The US-based clinical-stage developer of radiopharmaceuticals for cancer treatment will use the capital to advance its ATLAS clinical trial for advanced sarcomas, move a next-generation radioligand therapy candidate into clinical studies, and expand its discovery pipeline. Existing investors Duquesne Family Office and Bristol Myers Squibb participated in the round, joined by new investors Catalio Capital Management, Eli Lilly and Company, and Wasatch Group.